Dr. Patrick W. Gray, Chief Executive Officer and President
Dr. Gray has spent 35 years in the biotechnology industry, focusing on drug discovery for critical diseases. He has a passion for working in small companies with aggressive timelines—Genentech, ICOS, Macrogenics, Nura and Accelerator were all less than 60 employees when he joined. Dr. Gray’s career accomplishments include the first cloning and characterization of Hepatitis B surface antigen, Interferon-gamma, multiple Interferon-alpha genes, Lymphotoxin (TNF-beta), Bactericidal Permeability Increasing Protein, LPS-Binding Protein, Platelet Activating Factor Acetylhydrolase, CCR5 (subsequently shown to be the HIV co-receptor), Macrophage Derived Chemokine, and PI3K p110-delta. These discoveries led to numerous clinical trials, several approved human pharmaceuticals, and characterization of targets for therapeutic monoclonal antibodies and small molecules. In addition to his scientific accomplishments, Dr. Gray previously held senior scientific management positions, including Vice President, Chief Scientific Officer, and CEO. Dr. Gray received his Ph.D. in chemistry from the University of Colorado and his B.S. in biology from the University of Oregon. He is currently an affiliate professor at the University of Washington.
Dr. Reinhard Gabathuler, Senior Vice-President of Business Development
Dr Gabathuler obtained his PhD in Biochemistry at the Université de Lausanne, Switzerland, in 1982. He completed postdoctoral studies at the University of Washington, Seattle, WA, USA (1982-1985). He then went to the Swiss Institute for Cancer Research (ISREC) in Lausanne (1985-1987).
Following his experience in Lausanne, he took a research position in the newly formed Ludwig Institute for Cancer Research at the Karolinska Institute in Stockholm (1987-1991) pursuing his interest in the regulation of intracellular transport of receptors and proteins. He characterized the regulation of the expression of MHC Class I molecules in cancer cells and virus infected cells. In 1991, he took a research position at the Biotechnology Laboratory at the University of British Columbia in Vancouver, Canada. He developed and reconstituted immuno-recognition of cancer cells after introducing expression of TAP molecules. Dr Gabathuler joined AngioChem Inc. in 2004 as its Chief Scientific Officer and has applied his extensive knowledge in biochemistry, cell biology, and immunology to directing the R&D programs, advancing the company’s first product (ANG1005 now GRN1005) to IND application and into the clinic.
Ms. Judi Dalling LLB, CFO
Judi Dalling is a retired lawyer with experience in corporate and securities law. She also has a strong accounting background, having been controller and business manager of a major magazine publishing enterprise for over 20 years. Ms. Dalling currently works with various reporting companies, providing legal, accounting and administration services.
Dr. Wilfred Jefferies, Founding Scientist
Dr. Jefferies is a Professor at the University of British Columbia and is the scientific founder of the Company. He previously founded Synapse Technologies Inc., which was subsequently acquired by BioMarin Pharmaceuticals Inc. A world expert in identifying Biomarkers of Alzheimer’s disease and the delivery of drugs across the blood brain barrier. Dr. Jefferies holds a Bachelor of Science degree in Biochemistry from the University of Victoria and a Doctor of Philosophy degree from the Sir William Dunn School of Pathology at the University of Oxford. He is a Professor in the Michael Smith Laboratories at the University of British Columbia.